

Comprehensive guidelines translate research findings into clinical policy for HIV-infected transplant candidates and recipients

Michelle E. Roland^a and Peter G. Stock^b

^aDepartment of Internal Medicine, Division of AIDS, San Francisco General Hospital, University of California, San Francisco, California.

^bDepartment of Surgery, University of California, San Francisco, California, USA.

Introduction

The *GESIDA/GESITRA-SEIMC, SPNS and ONT Consensus Document on Solid Organ Transplantation in HIV-Infected Patients in Spain* published in this issue of *Spanish Journal of Infectious Diseases and Clinical Microbiology* represents a rigorous translation of recently acquired clinical research data to the clinical setting. This is the first national policy advocating solid organ transplant for carefully selected patients with HIV infection. Unfortunately, dramatic improvements in HIV-associated mortality and morbidity have come at the cost of frequent complications related to end-organ disease. Several small studies in the era of highly active antiretroviral therapy (HAART) suggest that patient and graft survival rates are similar to those in HIV-uninfected transplant recipients¹⁻¹⁴. Understandable fears of rapid HIV disease progression in the setting of post-transplant immunosuppression, reflected by CD4+ T-cell decline and the development of opportunistic infections and cancers, have not been realized. In fact, several immunosuppressive agents have antiretroviral properties¹⁵⁻²³. Despite complex interactions between immunosuppressants and antiretroviral agents, HIV viremia has remained successfully suppressed in most recipients.

HIV infection is not considered a contraindication to transplant by the United Network for Organ Sharing (UNOS), the agency responsible for deceased donor organ allocation policies in the United States. The traditional exclusion of HIV-infected patients at most transplant centers was borne in the early days of the HIV epidemic, when symptomatic HIV infection progressed rapidly and relentlessly. With transplant candidates dying on long waiting lists, the exclusion of a group with an especially poor underlying prognosis made sense on ethical grounds. Had these policies been developed in the current treatment era, however, it is likely that HIV-infected patients would have been assumed to be high risk, as are patients with hepatitis C infection (HCV) or diabetes, but would not have been excluded simply based upon HIV infection status.

While we are strong proponents of solid organ transplantation in selected HIV-infected patients, important

questions remain. Encouraging preliminary studies have been small and of relatively short duration. In addition, we have observed an unusually high incidence of rejection among our kidney transplant recipients that remains unexplained^{6,12}. Finally, the outcomes of HCV co-infected liver transplant recipients have been mixed, and several cases of rapid and severe recurrent HCV have been reported^{2,10,24,25}. As long as there is uncertainty, some will argue that it is unethical to utilize the deceased donor pool and thus deprive another transplant candidate from the benefit of that organ, or put living donors at risk. The amount of data required to resolve these concerns remains a contentious issue in the United States. We concur with the Spanish Consensus Document that sufficient data exist at this time^{26,27}. In fact, in the absence of data demonstrating poor outcomes, it can be reasonably argued that is no longer ethical to withhold this option from patients with HIV infection.

To definitively resolve these ethical and clinical dilemmas, it would be optimal for every willing HIV-infected transplant recipient to contribute by participating in a clinical outcomes study. Thus, it is important that coincident with the publication of this Consensus Document, the Spanish AIDS Foundation has provided funds to prospectively collect data related to all liver transplantation in Spain during 2005-07. We would advocate that additional funds be pursued to include all kidney transplant recipients as well.

The challenge now, as undertaken in the Consensus Document, is to develop patient selection and clinical management guidelines while we await definitive data describing predictors of good and poor outcomes. We will review several areas where the Spanish Consensus Document differs from the clinical trial protocol employed in the United States National Institutes of Health (NIH) sponsored 20-center study of liver and kidney transplantation. As noted by the authors of the Spanish Consensus Document, "this field is evolving continuously and the indications for transplant or management of these patients may change as more evidence becomes available. Therefore, this Committee undertakes to provide periodic updates of this document." We concur that reevaluation of existing data and flexibility are imperative in this rapidly evolving field.

Key Issues in Patient Selection

The goal of patient selection criteria is to offer transplantation to patients who are expected to tolerate immunosuppression without significant HIV disease progres-

Correspondencia: Dr. M.E. Roland.

Positive Health Program, San Francisco General Hospital, Ward 84, 995 Potrero Avenue, San Francisco, CA 94110, USA. Correo electrónico: mroland@php.ucsf.edu

Manuscrito recibido el 12-4-2005; aceptado el 15-4-2005.

sion. We believe such criteria should be applied to both deceased and living donor transplants. In this regard, we agree with the CD4+ T-cell count guidelines. We have seen no evidence of significant HIV disease progression at these CD4+ T-cell counts^{6,9,12}.

Control of HIV replication with HAART has resulted in dramatic improvement in immune function and survival. Thus, we agree that transplant candidates should be able to suppress HIV viremia whenever possible. Predicting the likelihood of complete HIV suppression with a new HAART regimen, however, can be challenging. Resistance testing at the time of evaluation to determine if there is a likely effective HAART regimen may be limited if the patient has discontinued HAART secondary to hepatotoxicity. Even on HAART, such tests may not detect mutations that are present in minority quasispecies due to remote antiretroviral use. Thus, the expert assessment of the potential for full virologic suppression must also take into account all prior resistance test results and any resistance predicted by past antiretroviral use in the context of ongoing viral replication.

We agree that it is unknown if antiretroviral therapy is necessary in the context of immunosuppression in patients who do not otherwise meet criteria to initiate HAART. We require HAART initiation in all patients except those who never had a detectable HIV RNA level because of concerns about potential enhanced viral replication post-transplant. It will be important to closely monitor patients who do not use HAART post-transplant for increases in HIV viremia and declines in CD4+ T-cell count as some immunosuppressive regimens may enable these patients to control their virus while others may exacerbate viral replication.

We excluded patients with any opportunistic infection or neoplasm history in our pilot study until 2002. Finding good preliminary outcomes, the protocol was modified to allow most opportunistic infections (OIs) with continued exclusion of progressive multifocal leukoencephalopathy (PML), chronic cryptosporidiosis, and visceral Kaposi's sarcoma (KS). We exclude PML because of 2 recent cases in HIV-infected transplant recipients and because there is no effective therapy for PML. Likewise, there is no effective therapy should chronic cryptosporidiosis recur post-transplant. Due to our positive experience with a subject with a history of pulmonary KS and our knowledge of another such patient²⁸, we decided to cautiously evaluate patients with a history of cutaneous KS. All OIs for which there are data demonstrating that it is safe to discontinue secondary prophylaxis with HAART-induced restoration of CD4+ T-cell counts have been included²⁹. We have seen no reactivation of OIs to date in 5 subjects with an OI history, and only 2 de novo OIs in our pilot cohort (1 case each of CMV and candida esophagitis)¹². Thus, we feel the Consensus Document exclusion of many AIDS-defining diseases based on the possibility of a greater risk of reactivation may be more conservative than necessary.

Key Issues in Utilization of Donors

The Consensus Document emphasizes the use of deceased donor organs, suggesting that the benefits of living donors may be limited and that the risks to both donor and recipient may be unacceptably high. In the case of living

donation, the risks and benefits to the potential donor and recipient must be considered carefully. In the context of long waiting lists and dialysis-associated morbidity, we believe that living kidney donation is a necessary option. The potential risk of accelerated HCV progression in living donor liver grafts (right lobe) must be weighed against the benefits of providing liver transplantation when the recipient is less ill. This is particularly problematic in the United States, where livers are allocated on the basis of disease severity, represented by the MELD score. Unfortunately, by the time the co-infected patient has a high enough MELD score to be allocated a deceased donor liver, they are often too sick to tolerate the procedure. We believe the potential for receiving a liver transplant prior to significant deterioration far outweighs the unknown increased risk of HCV recurrence in the setting of regeneration following living donor liver transplantation.

Because we often have waiting lists of several years, we have also utilized deceased organs considered to be at "high infectious risk," i.e. those that are serologically negative for HIV and hepatitis B and C but from a donor who may have engaged in behavior putting them at risk for recent acquisition. These donors are frequently turned down for kidney transplantation into HIV negative recipients who have the option of remaining on dialysis and have thus been an important source for kidney transplantation in HIV-infected patients. "High infectious risk" donors have been largely unavailable for liver transplantation into the HIV-infected patient, as these organs are commonly accepted for all liver transplant candidates. The issue of high-risk donors stands in contrast to the use of known HIV-infected donors. We agree with the Consensus Document that such organs carry the risk of super-infection with drug-resistant and/or more virulent HIV and should not be utilized until a study can be conducted to assess the safety of this approach.

Key Issues in Post-Transplant Clinical Management

Appreciating the diversity of immunosuppressant management protocols, the Consensus Document suggest that post-transplantation immunosuppressant and rejection therapy should be managed at each transplant center according to local protocols. This has been our practice as well, and it remains unclear what the optimal approaches to immunosuppression and rejection management are in this population. This question is complicated by complex drug-interactions, additive drug toxicities (e.g. hyperlipidemia and cytopenias) and frequent endocrinologic co-morbidities (e.g. insulin resistance) common in this population.

Rejection rates, especially among kidney transplant recipients, have been unexpectedly high in our experience^{6,12}, although less dramatic in a recent report from another transplant center³⁰. The high incidence of rejection may be related to insufficient immunosuppressant levels in the context of an activated or dysregulated immune system. Calcineurin-inhibitor (CI) pharmacokinetic parameters are altered by the use of protease inhibitors (PIs) and, to a lesser degree, non-nucleoside reverse transcriptase in-

hibitors (NNRTIs)^{31,32}. Thus, HIV-infected renal transplant recipients may be unable to tolerate “normal” CI trough levels without developing nephrotoxicity due to differences in HAART-associated drug exposure kinetics. There are numerous other potential explanations for the higher incidence of rejection which are being explored, but are beyond the scope of this editorial.

The use of IL-2 receptor inhibitor induction therapy has not eliminated early rejection episodes in HIV-infected kidney transplant recipients. There is currently interest in the use of cell-depleting induction therapy, which we cautiously support. Despite our initial near-prohibition of this practice, we have often had to utilize anti-lymphocyte preparations (Thymoglobulin), for the treatment of moderate to severe rejection episodes. Not surprisingly, there have been prolonged declines in CD4+ T-lymphocyte counts in these patients³³. While these patients have not developed AIDS-defining opportunistic infections, they have experienced other serious infections, including *staphylococcus aureus* endocarditis, influenza pneumonia, and pseudomonas sepsis. Thus, when indicated for the treatment of moderate to severe acute rejection we cautiously use these agents. However, we remain concerned about the marked lymphodepletion that persists for up to a year following administration.

Similar to the complexity of immunosuppression management, HAART management must be patient-specific. Some clinicians have interpreted the greater degree of pharmacologic interactions between the CIs and the PIs to mean that NNRTIs should be utilized instead of PIs. This is not necessarily the case, and several issues must be taken into account in making this decision. First, a PI may be indicated based on drug resistance or intolerance to the NNRTIs. Second, the use of nevirapine in a liver transplant recipient with a CD4+ T-cell count of greater than 250 for women or 400 for men should be undertaken with great caution³⁴. Third, efavirenz-induced hepatic metabolism results in increased CI dosing requirements which are not always well-tolerated. Although the interactions between PIs and CIs or sirolimus are very significant, we are learning how to dose these agents together and it can be done safely. Until a center develops expertise with these drug interactions in various patient populations, we encourage active consultations with an experienced center for advice about initial immunosuppressant doses based upon the HAART regimen, the frequency of monitoring, and anticipated changes in immunosuppressant dosing over time as a result of ongoing metabolic and pharmacologic changes.

The critical antiviral choices in hepatitis B- (HBV) infected patients also deserves special mention, as noted in the Consensus Document. Parenthetically, some HBV-HIV co-infected liver transplant candidates with lamivudine resistant HBV may be found to be under-managed at the time of transplant evaluation. In such cases, the need for transplant may be delayed substantially with the addition of tenofovir or adefovir. Entecavir availability will expand management options further.

The thoughtful management of HAART agents in the post-transplant period is critical. The advice that “HAART must be administered again as soon as the patient begins to receive food orally” is important in the case of the HBV-HIV co-infected transplant recipient in order to minimize the risk of developing HIV resistance to agents

that are active against both HIV and HBV. In other cases, it is more important to reinitiate HAART when the patient is likely to tolerate it and not experience interruptions in dosing. We have not experienced bad outcomes as a result of moderately delaying reinitiation of HAART.

Finally, it is critical that any change being considered in the HAART regimen post-transplant be discussed with the member of the transplant team managing the immunosuppressants before the change is made. There have been rejection episodes and even a death that resulted from a PI being discontinued without such communication, resulting in very low immunosuppressant levels. Ideally, all drug changes would be communicated as even some antibiotics and antifungals can have dramatic pharmacokinetic effects. Knowledge about these complex drug interactions evolves rapidly. For example, many potential transplant candidates come to evaluation using the PI atazanavir which cannot be used with a proton-pump inhibitor (PPI). PPIs are used indefinitely in many transplant recipients. Although a database of drug interactions has been provided in the Consensus Document, expert pharmacologic consultation should be utilized both prior to and following transplantation by centers with limited experience.

In addition to standard post-transplant prophylaxis, we recommend institution of HIV-associated prophylaxis against *mycobacterium avium complex* (MAC) if the CD4+ T-cell count declines below 50. If patients with an OI history are provided with a transplant, then secondary prophylaxis should be reinstated if the CD4+ T-cell count declines and/or treatment for acute rejection is required. Unfortunately, there are also some opportunistic complications for which we do not have prophylaxis. In the case of HPV, surveillance for cervical and ano-rectal intraepithelial neoplasia and cancer should be performed. Finally, disease caused by HHV8 should be considered in cases of unexplained hepatitis and/or bone marrow suppression.

Prevention of HIV transmission to healthcare workers

The potential for HIV transmission to healthcare workers during surgery (especially with a high-risk procedure like liver transplantation) and in the peri-transplant period is small but not trivial³⁵. Consideration of appropriate regimens for post-exposure prophylaxis (PEP) should be part of the pre-transplant evaluation. If HAART regimens are modified prior to transplant, PEP recommendations should be reevaluated. Availability of PEP medications and consultation about the management of the exposed healthcare worker should be a priority. Concerns about HIV transmission have prevented several American surgeons from embracing liver transplantation in co-infected patients. In order to reduce the risk of transmission alone, it is appropriate to make every attempt to suppress plasma HIV prior to liver transplant if HAART can be tolerated.

Conclusion

As noted in the Consensus Document, the selection of HIV-infected patients for solid organ transplantation and their subsequent care is complex and requires excellent

communication among all members of a truly multidisciplinary team. The need for such communication extends to the patient and their primary care provider as well, as many patients will receive the bulk of their medical care close to home rather than at the transplant center. The multidisciplinary nature of the authors of this Consensus Document, as well as the early successes with transplantation in Spain, bode well for the Spanish patient seeking transplantation. We look forward to learning from the continuing experience of our Spanish colleagues in the coming years.

References

- Miró JM, Torre-Cisneros J, Moreno A, Tuset M, Quereda C, Laguno M, et al. Documento de consenso GESIDA/GESITRA-SEIMC, SPNS y ONT sobre trasplante de órgano sólido en pacientes infectados por el VIH en España (marzo 2005). *Enferm Infecc Microbiol Clin*. 2005;23:353-62.
- Moreno S, Fortún J, Quereda C, Moreno A, Pérez-Eliás MJ, Martín-Dávila P, et al. Liver transplantation in HIV-infected recipients. *Liver Transpl*. 2005;11:76-81.
- Teicher E, Duclos-Valles J, Azulay D, Castaing D, Bismuth H, Roque-Afonso A, et al. Liver transplantation in HIV-HCV co-infected patients. San Francisco: 11th Conference on Retroviruses and Opportunistic Infections; 2004. [Abstract #828.]
- Rufi G, Vargas V, Valdivieso A, Miró JM, Salcedo M, Rafecas A, et al, and the Spanish OLT-HIV Working Group. Orthotopic liver transplantation in 15 HIV-1-infected recipients: Evaluation of Spanish experience in the HAART era (2002-2003). San Francisco: 11th Conference on Retroviruses and Opportunistic Infections; 2004. [Abstract #827.]
- Vogel M, Effenberger W, Wolff M, Rockstroh JK, Hirner A, Sauerbruch T, et al. Clinical outcome of orthotopic liver transplantation in HIV-infected patients – a report of 4 cases from the Bonn cohort. *Eur J Med Res*. 2003; 8 Suppl 1:71.
- Stock PG, Roland ME, Carlson L, Freise CE, Roberts JP, Hirose R, et al. Kidney and liver transplantation in human immunodeficiency virus-infected patients: a pilot safety and efficacy study. *Transplantation*. 2003;76:370-5.
- Samuel D, Duclos-Valles JC, Teicher E, Vittecoq D. Liver transplantation in patients with HIV infection. *J Hepatol*. 2003;39:3-6.
- Roland ME, Havlir DV. Responding to organ failure in HIV-infected patients. *N Engl J Med*. 2003;348:2279-81.
- Roland ME, Stock PG. Review of solid-organ transplantation in HIV-infected patients. *Transplantation*. 2003;75:425-9.
- Ragni MV, Belle SH, Im K, Neff G, Roland M, Stock P, et al. Survival of human immunodeficiency virus-infected liver transplant recipients. *J Infect Dis*. 2003;188:1412-20.
- Neff GW, Bonham A, Tzakis AG, Ragni M, Jayaweera D, Schiff ER, et al. Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease. *Liver Transpl*. 2003;9:239-47.
- Roland M, Carlson L, Frassetto L, Murphy B, Keller M, Olthoff K, et al. 1-to-3-year outcomes in HIV-infected liver and kidney transplant recipients. Boston: 12th Conference on Retroviruses and Opportunistic Infections; 2005. [Abstract #953.]
- Vogel MVE, Wasmuth JC, Brackmann H, Goldmann G, Wolff M, Hirner A, et al. Orthotopic liver transplantation in HIV-positive patients: Outcome of 10 patients from the Bonn cohort. Boston: 12th Conference on Retroviruses and Opportunistic Infections; 2005. [Abstract #931.]
- Abbott KC, Swanson SJ, Agodoa LY, Kimmel PL. Human immunodeficiency virus infection and kidney transplantation in the era of highly active antiretroviral therapy and modern immunosuppression. *J Am Soc Nephrol*. 2004;15:1633-9.
- García F, Plana M, Arnedo M, Brunet M, Castro P, Gil C, et al. Effect of mycophenolate mofetil on immune response and plasma and lymphatic tissue viral load during and after interruption of highly active antiretroviral therapy for patients with chronic HIV infection: A randomized pilot study. *J Acquir Immune Defic Syndr*. 2004;36:823-30.
- Rizzardi GP, Lazzarin A, Pantaleo G. Potential role of immune modulation in the effective long-term control of HIV-1 infection. *J Biol Regul Homeost Agents*. 2002;16:83-90.
- Rizzardi GP, Harari A, Capiluppi B, Tambussi G, Ellefsen K, Ciuffreda D, et al. Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy. *J Clin Invest*. 2002;109:681-8.
- Margolis DM, Kewn S, Coull JJ, Ylisastigui L, Turner D, Wise H, et al. The addition of mycophenolate mofetil to antiretroviral therapy including abacavir is associated with depletion of intracellular deoxyguanosine triphosphate and a decrease in plasma HIV-1 RNA. *J Acquir Immune Defic Syndr*. 2002;31:45-9.
- Sereti I, Lane HC. Immunopathogenesis of human immunodeficiency virus: implications for immune-based therapies. *Clin Infect Dis*. 2001;32:1738-55.
- Coull JJ, Turner D, Melby T, Betts MR, Lanier R, Margolis DM. A pilot study of the use of mycophenolate mofetil as a component of therapy for multidrug-resistant HIV-1 infection. *J Acquir Immune Defic Syndr*. 2001;26: 423-34.
- Rizzardi GP, Vaccarezza M, Capiluppi B, Tambussi G, Lazzarin A, Pantaleo G. Cyclosporin A in combination with HAART in primary HIV-1 infection. *J Biol Regul Homeost Agents*. 2000;14:79-81.
- Heredia A, Margolis D, Oldach D, Hazen R, Le N, Redfield R. Abacavir in combination with the inosine monophosphate dehydrogenase (IMPDH)-inhibitor mycophenolic acid is active against multidrug-resistant HIV-1. *J Acquir Immune Defic Syndr*. 1999;22:406-7.
- Heredia A, Amoroso A, Davis C, Le N, Reardon E, Dominique JK, et al. Rapamycin causes down-regulation of CCR5 and accumulation of anti-HIV beta-chemokines: an approach to suppress R5 strains of HIV-1. *Proc Natl Acad Sci U S A*. 2003;100:10411-6.
- Prachalias AA, Pozniak A, Taylor C, Srinivasan P, Muiesan P, Wendon J, et al. Liver transplantation in adults coinfecting with HIV. *Transplantation*. 2001;72:1684-8.
- Tolan DJ, Davies MH, Millson CE. Fibrosing cholestatic hepatitis after liver transplantation in a patient with hepatitis C and HIV infection. *N Engl J Med*. 2001;345:1781.
- Halpern SD, Ubel PA, Caplan AL. Solid-organ transplantation in HIV-infected patients. *N Engl J Med*. 2002;347:284-7.
- Roland ME, Lo B, Braff J, Stock PG. Key clinical, ethical, and policy issues in the evaluation of the safety and effectiveness of solid organ transplantation in HIV-infected patients. *Arch Intern Med*. 2003;163:1773-8.
- Calabrese LH, Albrecht M, Young J, McCarthy P, Haug M, Jarcho J, et al. Successful cardiac transplantation in an HIV-1-infected patient with advanced disease. *N Engl J Med*. 2003;348:2323-8.
- 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with Human Immunodeficiency Virus. USPHS/IDSA Prevention of Opportunistic Infections Working Group. *Infectious Diseases Society of American*. MMWR; 1999. p. 48.
- Kumar MS, Sierka DR, Damask AM, Fyfe B, McAlack RF, Heifets M, et al. Safety and success of kidney transplantation and concomitant immunosuppression in HIV-positive patients. *Kidney Int*. 2005;67:1622-9.
- Frassetto L, Aggarwal AM, Bucher P, Jacobsen W, Christians U, Benet LZ, et al. Pharmacokinetic interactions between cyclosporine and protease inhibitors in HIV+ subjects. *Drug Metabol Pharmacokin*. 2003;18:114-20.
- Jain AK, Venkataramanan R, Fridell JA, Gadowski M, Shaw LM, Ragni M, et al. Nelfinavir, a protease inhibitor, increases sirolimus levels in a liver transplantation patient: a case report. *Liver Transpl*. 2002;8:838-40.
- Carter JT MM, Carlson LL, Roland ME, Freise CE, Hirose R, Stock PG. Safety and efficacy of thymoglobulin in HIV-positive renal transplant recipients. Seattle: American Transplant Congress; 2005. [Abstract #1537.]
- DHHS U. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents: US Department of Health and Human Services; 2005.
- CDC. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. MMWR. 2001.